Статья
Гипертрофическая кардиомиопатия. Клинические рекомендации 2020
Российское кардиологическое общество (РКО)При участии: Ассоциации сердечно-сосудистых хирургов России (АССХ)Одобрено Научно-практическим Советом Минздрава Российской Федерации Президиум рабочей группы: Габрусенко С. А., Гудкова А. Я.*, Козиолова Н. А.Рабочая группа: Александрова С. А., Берсенева М. И., Гордеев М. Л., Дземeшкевич С. Л., Заклязьминская Е. В., Иртюга О. Б., Каплунова В. Ю., Костарева А. А., Крутиков А. Н., Маленков Д. А., Новикова Т. Н., Саидова М. А., Санакоев М. К., Стукалова О. В.
1. Габрусенко С. А., Селезнёв Д. М., Наумов В. Г. Генетические аспекты гипертрофической кардиомиопатии (обзор литературы). Практикующий врач. 2000;18(2):2-5.
2. Шляхто Е. В., Гудкова А. Я., Костарева А. А. Первичные кардиомиопатии, современное представление. Терапевтический архив. 2005;77(12):77-83.
3. Gersh BJ, Maron BJ, Bonow RO, et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):2761-96. doi:10.1161/CIR.0b013e318223e230.
4. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi:10.1093/eurheartj/ehu284.
5. Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17(11):880-8. doi:10.1038/gim.2014.205. Erratum in: Genet Med. 2015;17(4):319.
6. Coats CJ, Elliott PM. Genetic biomarkers in hypertrophic cardiomyopathy. Biomark Med. 2013;7(4):505-16. doi:10.2217/bmm.13.79.
7. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363(9424):1881-91. doi:10.1016/S0140-6736(04)16358-7.
8. Kelly MA, Caleshu C, Morales A, et al. Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen's Inherited Cardiomyopathy Expert Panel. Genet Med. 2018;20(3):351-9. doi:10.1038/gim.2017.218.
9. Kokado H, Shimizu M, Yoshio H, et al. Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. Circulation. 2000;102(6):663-9. doi:10.1161/01.cir.102.6.663.
10. Kostareva A, Gudkova A, Sjöberg G, et al. Deletion in TNNI3 gene is associated with restrictive cardiomyopathy. Int J Cardiol. 2009;131(3):410-2. doi:10.1016/j.ijcard.2007.07.108.
11. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287(10):1308-20. doi:10.1001/jama.287.10.1308.
12. Maron BJ, Maron MS, Maron BA, Loscalzo J. Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(15):1978-86. doi:10.1016/j.jacc.2019.01.061.
13. Mogensen J, Murphy RT, Kubo T, et al. Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44(12):2315-25. doi:10.1016/j.jacc.2004.05.088.
14. Селезнёв Д. М., Габрусенко С. А., Парфенова Е. В. и др. Роль мутаций в гене тяжелой цепи сердечного бета-миозина в российской популяции больных с гипертрофической кардиомиопатией. Кардиология. 2005;45(4):15-20.
15. Туральчук М. В., Новик Г. А., Гудкова А. Я. Особенности течения кардиомиопатий с рестриктивным фенотипом, обусловленных мутациями генов сердечного тропонина I и десмина, и алгоритмы их диагностики. Педиатрическая фармакология. 2011;8(4):112-6.
16. Burton D, Abdulrazzak H, Knott A, et al. Two mutations in troponin I that cause hypertrophic cardiomyopathy have contrasting effects on cardiac muscle contractility. Biochem J. 2002;362(Pt 2):443-51. doi:10.1042/0264-6021:3620443.
17. Zhou N, Qin S, Liu Y, et al. Whole-exome sequencing identifies rare compound heterozygous mutations in the MYBPC3 gene associated with severe familial hypertrophic cardiomyopathy. Eur J Med Genet. 2018;61(8):434-41. doi:10.1016/j.ejmg.2018.03.001.
18. Charron P, Forissier JF, Amara ME, et al. Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population. Int J Cardiol. 2003;90(1):33-8; discussion 38-40. doi:10.1016/s0167-5273(02)00534-x.
19. Lopes LR, Murphy C, Syrris P, et al. Use of high-throughput targeted exome-sequencing to screen for copy number variation in hypertrophic cardiomyopathy. Eur J Med Genet. 2015;58(11):611-6. doi:10.1016/j.ejmg.2015.10.001.
20. European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA), Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013;15(8):1070-118. doi:10.1093/europace/eut206.
21. Hiemstra YL, Debonnaire P, van Zwet EW, et al. Development of and Progression of Overt Heart Failure in Nonobstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2018;122(4):656-62. doi:10.1016/j.amjcard.2018.04.038.
22. Ho CY, Day SM, Colan SD, et al.; HCMNet Investigators. The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study. JAMA Cardiol. 2017;2(4):419-28. doi:10.1001/jamacardio.2016.5670.
23. Hodatsu A, Konno T, Hayashi K, et al. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models. Am J Physiol Heart Circ Physiol. 2014;307(11):H1594-604. doi:10.1152/ajpheart.00637.2013.
24. Horimoto M, Yokota K, Inoue H, et al. Development of obstructive hypertrophic cardiomyopathy from nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 1998;82(3):403-5. doi:10.1016/s0002-9149(98)00337-3.
25. Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol. 2004;30(3):178-81. doi:10.1002/dc.10370.
26. Canepa M, Sorensen LL, Pozios I, et al. Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy. Am J Cardiol. 2013;112(8):1182-9. doi:10.1016/j.amjcard.2013.05.070.
27. Charron P, Arad M, Arbustini E, et al.; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31(22):2715-26. doi:10.1093/eurheartj/ehq271.
28. Finocchiaro G, Magavern E, Sinagra G, et al. Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2017;6(12):e007161. doi:10.1161/JAHA.117.007161.
29. Bos JM, Ommen SR, Ackerman MJ. Genetics of hypertrophic cardiomyopathy: one, two, or more diseases? Curr Opin Cardiol. 2007;22(3):193-9. doi:10.1097/HCO.0b013e3280e1cc7f.
30. Richards S, Aziz N, Bale S, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24. doi:10.1038/gim.2015.30.
31. Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017;121(7):749-70. doi:10.1161/CIRCRESAHA.117.311059.
32. Бокерия Л. А., Гудкова А. Я., Созин С. Е. и др. Экспрессия генов матриксной металлопротеиназы-1 (ММР-1), тканевого ингибитора матриксных металлопротеиназ-1 (TIMP-1), коллагена I и III типов в миокарде больных идиопатической гипертрофической кардиомиопатией. Бюллетень НЦССХ им. А. Н. Бакулева РАМН. 2005;6(4):35-42.
33. Гудкова А. Я., Рыбакова М. Г., Шляхто Е. В., Бокерия Л. А. Гипертрофическая кардиомиопатия. Клинико-морфологические сопоставления. Архив патологии. 2012;74(4):8-11.
34. Гудкова А. Я. Характеристика течения обструктивной гипертрофической кардиомиопатии у взрослых (обзор литературы и результаты собственных исследований). Артериальная гипертензия. 2008;14(2), Приложение 2:39-49.
35. Гудкова А. Я., Шляхто Е. В. Клеточные механизмы гипертрофии миокарда при гипертрофической кардиомиопатии и эссенциальной артериальной гипертензии. Артериальная гипертензия. 2008;14(4):373-80.
36. Shliakhto EV, Bokeriia LA, Rybakova MG, et al. Cellular aspects of hypertrophic cardiomyopathy pathogenesis: the role of cardiomyocyte polyploidy and activation of the proliferating cell nuclear antigen in the myocardium. Tsitologiia. 2007;49(10):817-23.
37. Frustaci A, Russo MA, Chimenti C. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy. Hum Pathol. 2013;44(1):133-41. doi:10.1016/j.humpath.2012.04.023.
38. Leone O, Veinot JP, Angelini A, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21(4):245-74. doi:10.1016/j.carpath.2011.10.001.
39. Philipson DJ, DePasquale EC, Yang EH, Baas AS. Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy. Heart Fail Rev. 2017;22(6):879-88. doi:10.1007/s10741-017-9648-x.
40. Roberts R, Sigwart U. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy. Circulation. 2005;112(2):293-6. doi:10.1161/01.CIR.0000146788.30724.0A.
41. Varnava AM, Elliott PM, Sharma S, et al. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000;84(5):476-82. doi:10.1136/heart.84.5.476.
42. Зайцев В. В., Гурщенков А. В., Митрофанова Л. Б. и др. Клиническое значение различных методов оценки миокардиального фиброза при гипертрофической кардиомиопатии. Кардиология. 2020;60(3):44-50. doi:10.18087/cardio.2020.3.n561.
43. Arbustini E, Narula N, Dec GW, et al. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol. 2013;62(22):2046-72. doi:10.1016/j.jacc.2013.08.1644. Erratum in: J Am Coll Cardiol. 2014;63(2):191-4.
44. Barcia G, Rachid M, Magen M, et al. Pitfalls in molecular diagnosis of Friedreich ataxia. Eur J Med Genet. 2018;61(8):455-8. doi:10.1016/j.ejmg.2018.03.004.
45. Bokhari S, Castaño A, Pozniakoff T, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195-201. doi:10.1161/CIRCIMAGING.112.000132.
46. Charron P, Villard E, Sébillon P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart. 2004;90(8):842-6. doi:10.1136/hrt.2003.029504.
47. Cook A, Giunti P. Friedreich's ataxia: clinical features, pathogenesis and management. Br Med Bull. 2017;124(1):19-30. doi:10.1093/bmb/ldx034.
48. D'Souza A, Theis JD, Vrana JA, et al. Localized insulin-derived amyloidosis: a potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. Am J Hematol. 2012;87(11):E131-2. doi:10.1002/ajh.23334.
49. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97(1):75-84. doi:10.1136/hrt.2009.190405.
50. Frustaci A, Chimenti C, Doheny D, Desnick RJ. Evolution of cardiac pathology in classic Fabry disease: Progressive cardiomyocyte enlargement leads to increased cell death and fibrosis, and correlates with severity of ventricular hypertrophy. Int J Cardiol. 2017;248:257-62. doi:10.1016/j.ijcard.2017.06.079.
51. Monserrat L, Gimeno-Blanes JR, Marín F, et al. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007;50(25):2399-403. doi:10.1016/j.jacc.2007.06.062.
52. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086-97. doi:10.1016/S1474-4422(11)70246-0.
53. Quarta CC, Guidalotti PL, Longhi S, et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc Imaging. 2012;5(7):755-8. doi:10.1016/j.jcmg.2012.02.015.
54. RDTF Report: European reference networks in the field of Rare Diseases: State of the art and Future Directions. Jul, 2008. http://www.eucerd.eu/upload/file/Publication/RDTFERN2008.pdf.
55. Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6(3):392-8. doi:10.1161/CIRCIMAGING.112.000070.
56. Tsai SB, Seldin DC, Wu H, et al. Myocardial infarction with "clean coronaries" caused by amyloid light-chain AL amyloidosis: a case report and literature review. Amyloid. 2011;18(3):160-4. doi:10.3109/13506129.2011.571319.
57. Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008;51(10):1022-30. doi:10.1016/j.jacc.2007.10.049.
58. Wilkinson JD, Lowe AM, Salbert BA, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2012;164(3):442-8. doi:10.1016/j.ahj.2012.04.018.
59. Yang Z, Vatta M. Danon disease as a cause of autophagic vacuolar myopathy. Congenit Heart Dis. 2007;2(6):404-9. doi:10.1111/j.1747-0803.2007.00132.x.
60. Yang Z, McMahon CJ, Smith LR, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation. 2005;112(11):1612-7. doi:10.1161/CIRCULATIONAHA.105.546481.
61. Ibrahim M, Rao C, Ashrafian H, et al. Modern management of systolic anterior motion of the mitral valve. Eur J Cardiothorac Surg. 2012;41(6):1260-70. doi:10.1093/ejcts/ezr232.
62. Deng L, Huang X, Yang C, et al. Numerical simulation study on systolic anterior motion of the mitral valve in hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2018;266:167-73. doi:10.1016/j.ijcard.2018.01.062.
63. Manabe S, Kasegawa H, Arai H, Takanashi S. Management of systolic anterior motion of the mitral valve: a mechanism-based approach. Gen Thorac Cardiovasc Surg. 2018;66(7):379-89. doi:10.1007/s11748-018-0915-0.
64. Ro R, Halpern D, Sahn DJ, et al. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular flow and the mitral valve. J Am Coll Cardiol. 2014;64(19):1984-95. doi:10.1016/j.jacc.2014.04.090.
65. Hymel BJ, Townsley MM. Echocardiographic assessment of systolic anterior motion of the mitral valve. Anesth Analg. 2014;118(6):1197-201. doi:10.1213/ANE.0000000000000196.
66. Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2000;36(4):1344-54. doi:10.1016/s0735-1097(00)00830-5.
67. Silbiger JJ. Abnormalities of the Mitral Apparatus in Hypertrophic Cardiomyopathy: Echocardiographic, Pathophysiologic, and Surgical Insights. J Am Soc Echocardiogr. 2016;29(7):622-39. doi:10.1016/j.echo.2016.03.003.
68. Shah JS, Esteban MT, Thaman R, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart. 2008;94(10):1288-94. doi:10.1136/hrt.2007.126003.
69. Geske JB, Sorajja P, Ommen SR, Nishimura RA. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2011;4(6):704-9. doi:10.1016/j.jcin.2011.02.014.
70. Efthimiadis GK, Pagourelias ED, Parcharidou D, et al. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction. Circ J. 2013;77(9):2366-74. doi:10.1253/circj.cj-12-1561.
71. Minami Y, Kajimoto K, Terajima Y, et al. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011;57(23):2346-55. doi:10.1016/j.jacc.2011.02.033.
72. Yan LR, Zhao SH, Wang HY, et al. Clinical characteristics and prognosis of 60 patients with midventricular obstructive hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2015;16(11):751-60. doi:10.2459/JCM.0000000000000163.
73. Hang D, Schaff HV, Ommen SR, et al. Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2018;155(5):2096-102. doi:10.1016/j.jtcvs.2017.10.054.
74. Pacheco Claudio C, Quesada O, Pepine CJ, Noel Bairey Merz C. Why names matter for women: MINOCA/INOCA (myocardial infarction/ischemia and no obstructive coronary artery disease). Clin Cardiol. 2018;41(2):185-93. doi:10.1002/clc.22894.
75. Аверкина Н. В., Габрусенко С. А., Овчинников А. Г. и др. Оценка перфузии миокарда у больных с гипертрофической кардиомиопатией в сопоставлении с клиническими и эхокардиографическими данными. Терапевтический архив. 2003;78(4):20-5.
76. Аверков О. В., Барбараш О. Л., Бойцов С. А. и др. Дифференцированный подход в диагностике, формулировке диагноза, ведении больных и статистическом учете инфаркта миокарда 2 типа (согласованная позиция). Российский кардиологический журнал. 2019;(6):7-21. doi:10.15829/1560-4071-2019-6-7-21.
77. Каплунова В. Ю., Шакарьянц В. А., Кожевникова М. В. и др. Гипертрофическая кардиомиопатия и ишемическая болезнь сердца. Варианты сочетанной патологии. Кардиология. 2017;57(12):16-24. doi:10.18087/cardio.2017.12.10062.
78. Костин С. И. Морфологические и морфометрические особенности гипертрофической кардиомиопатии. Архив патологии. 1989;51(1):47-52.
79. Мухарлямов Н. Кардиомиопатии. Москва, 1990. с.283. ISBN 5-225-02119-0.
80. Aletras AH, Tilak GS, Hsu LY, Arai AE. Heterogeneity of intramural function in hypertrophic cardiomyopathy: mechanistic insights from MRI late gadolinium enhancement and high-resolution displacement encoding with stimulated echoes strain maps. Circ Cardiovasc Imaging. 2011;4(4):425-34. doi:10.1161/CIRCIMAGING.110.958751.
81. Camici PG, Olivotto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol. 2012;52(4):857-64. doi:10.1016/j.yjmcc.2011.08.028.
82. Einarsen E, Cramariuc D, Lønnebakken MT, et al. Comparison of Frequency of Ischemic Cardiovascular Events in Patients With Aortic Stenosis With Versus Without Asymmetric Septal Hypertrophy (from the SEAS Trial). Am J Cardiol. 2017;119(7):1082-7. doi:10.1016/j.amjcard.2016.11.064.
83. Foà A, Agostini V, Rapezzi C, et al. Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. Int J Cardiol. 2019;291:77-82. doi:10.1016/j.ijcard.2019.03.060.
84. Kwon DH, Smedira NG, Rodriguez ER, et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol. 2009;54(3):242-9. doi:10.1016/j.jacc.2009.04.026.
85. Maron MS, Olivotto I, Maron BJ, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54(9):866-75. doi:10.1016/j.jacc.2009.04.072.
86. Mundhenke M, Schwartzkopff B, Strauer BE. Structural analysis of arteriolar and myocardial remodelling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy. Virchows Arch. 1997;431(4):265-73. doi:10.1007/s004280050098.
87. Nakamura T, Sakamoto K, Yamano T, et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(10):1657-63. doi:10.1016/s0735-1097(02)01813-2.
88. Raphael CE, Cooper R, Parker KH, et al. Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy: Insights From Wave Intensity Analysis and Magnetic Resonance. J Am Coll Cardiol. 2016;68(15):1651-60. doi:10.1016/j.jacc.2016.07.751.
89. Sciagrà R, Calabretta R, Cipollini F, et al. Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study. Eur J Nucl Med Mol Imaging. 2017;44(5):866-75. doi:10.1007/s00259-016-3603-2.
90. Shin YJ, Lee JH, Yoo JY, et al. Clinical significance of evaluating coronary atherosclerosis in adult patients with hypertrophic cardiomyopathy who have chest pain. Eur Radiol. 2019;29(9):4593-602. doi:10.1007/s00330-018-5951-8.
91. Liu W, Sun D, Yang J. Diastolic Dysfunction of Hypertrophic Cardiomyopathy Genotype-Positive Subjects Without Hypertrophy Is Detected by Tissue Doppler Imaging: A Systematic Review and Meta-analysis. J Ultrasound Med. 2017;36(10):2093-103. doi:10.1002/jum.14250.
92. Covella M, Rowin EJ, Hill NS, et al. Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. Circ Heart Fail. 2017;10(4):e003689. doi:10.1161/CIRCHEARTFAILURE.116.003689.
93. Germans T, Rüssel IK, Götte MJ, et al. How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12(1):13. doi:10.1186/1532-429X-12-13.
94. Huang X, Yue Y, Wang Y, et al. Assessment of left ventricular systolic and diastolic abnormalities in patients with hypertrophic cardiomyopathy using real-time three-dimensional echocardiography and two-dimensional speckle tracking imaging. Cardiovasc Ultrasound. 2018;16(1):23. doi:10.1186/s12947-018-0142-y.
95. Matsumura Y, Elliott PM, Virdee MS, et al. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity. Heart. 2002;87(3):247-51. doi:10.1136/heart.87.3.247.
96. Бокерия Л. А., Борисов К. В., Синев А. Ф. Улучшение диастолической функции левого и правого желудочков сердца после хирургической коррекции гипертрофической обструктивной кардиомиопатии при помощи оригинального способа. Грудная и сердечно-сосудистая хирургия. 1999;(4):4-10.
97. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114(3):216-25. doi:10.1161/CIRCULATIONAHA.105.583500.
98. Biagini E, Spirito P, Rocchi G, et al. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol. 2009;104(12):1727-31. doi:10.1016/j.amjcard.2009.07.057.
99. Bravo PE, Luo HC, Pozios I, et al. Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype? Eur Heart J Cardiovasc Imaging. 2016;17(3):293-300. doi:10.1093/ehjci/jev154.
100. Fernández A, Vigliano CA, Casabé JH, et al. Comparison of prevalence, clinical course, and pathological findings of left ventricular systolic impairment versus normal systolic function in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2011;108(4):548-55. doi:10.1016/j.amjcard.2011.03.083.
101. Melacini P, Basso C, Angelini A, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010;31(17):2111-23. doi:10.1093/eurheartj/ehq136.
102. Maron MS, Hauser TH, Dubrow E, et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol. 2007;100(8):1293-8. doi:10.1016/j.amjcard.2007.05.061.
103. Falcone DM, Moore D, Lambert EC. Idiopathic hypertrophic cardiomyopathy involving the right ventricle. Am J Cardiol. 1967;19(5):735-40. doi:10.1016/0002-9149(67)90480-8.
104. Shimizu M, Kawai H, Yokota Y, Yokoyama M. Echocardiographic assessment of right ventricular obstruction in hypertrophic cardiomyopathy. Circ J. 2003;67(10):855-60. doi:10.1253/circj.67.855.
105. Бокерия Л. А., Борисов К. В. Обструктивная гипертрофическая кардиомиопатия: методы хирургической коррекции. Грудная и сердечно-сосудистая хирургия. 1997;(1):61-5.
106. Бокерия Л. А., Борисов К. В., Синев А. Ф. и др. Результаты медикаментозного и хирургического лечения гипертрофической кардиомиопатии с обструкцией выводных отделов левого и правого желудочков сердца. Грудная и сердечно-сосудистая хирургия. 2004;2:4-9.
107. Бокерия Л. А., Борисов К. В., Синев А. Ф., Шевердина В. В. Хирургическая коррекция ранее неоперабельных форм гипертрофической обструктивной кардиомиопатии. Грудная и сердечно-сосудистая хирургия. 1999;(6):130-6.
108. Pagourelias ED, Efthimiadis GK, Parcharidou DG, et al. Prognostic value of right ventricular diastolic function indices in hypertrophic cardiomyopathy. Eur J Echocardiogr. 2011;12(11):809-17. doi:10.1093/ejechocard/jer126.
109. Shah JP, Yang Y, Chen S, et al. Prevalence and Prognostic Significance of Right Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2018;122(11):1932-8. doi:10.1016/j.amjcard.2018.08.043.
110. Кактурский Л. Внезапная смерть (клиническая морфология). Москва, 2000. с.126. ISBN 5-93649-001-7.
111. Ревишвили А. Ш., Бойцов С. А., Давтян К. В. и др. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Москва, 2017. с. 701. https://vnoa.ru/upload/Recomendation_2017_30_10_2017_HR.pdf. ISBN 978-5-9500922-0-6.
112. Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(5):697-704. doi:10.1016/j.jacc.2004.11.043.
113. Zipes DP, Camm AJ, Borggrefe M, et al.; American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8(9):746-837. doi:10.1093/europace/eul108.
114. Czosek RJ, Jefferies JL, Khoury PR, et al. Arrhythmic Burden and Ambulatory Monitoring of Pediatric Patients with Cardiomyopathy. Pacing Clin Electrophysiol. 2016;39(5):443-51. doi:10.1111/pace.12835.
115. Desai M, Mentias A. Risk stratification in hypertrophic cardiomyopathy. Aging (Albany NY). 2019;11(6):1617-8. doi:10.18632/aging.101895.
116. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36(7):2212-8. doi:10.1016/s0735-1097(00)01003-2.
117. Goyal V, Jassal DS, Dhalla NS. Pathophysiology and prevention of sudden cardiac death. Can J Physiol Pharmacol. 2016;94(3):237-44. doi:10.1139/cjpp-2015-0366.
118. Marrakchi S, Kammoun I, Bennour E, et al. Risk stratification in hypertrophic cardiomyopathy. Herz. 2020;45(1):50-64.. doi:10.1007/s00059-018-4700-8.
119. Weissler-Snir A, Adler A, Williams L, et al. Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge. Eur Heart J. 2017;38(22):1728-37. doi:10.1093/eurheartj/ehw268.
120. Weissler-Snir A, Chan RH, Adler A, et al. Usefulness of 14-Day Holter for Detection of Nonsustained Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2016;118(8):1258-63. doi:10.1016/j.amjcard.2016.07.043.
121. Goff ZD, Calkins H. Sudden death related cardiomyopathies – Hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2019;62(3):212-6. doi:10.1016/j.pcad.2019.04.001.
122. Bois JP, Adams JC, Kumar G, et al. Relation Between Temperature Extremes and Symptom Exacerbation in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2016;117(6):961-5. doi:10.1016/j.amjcard.2015.12.046.
123. Haghjoo M, Faghfurian B, Taherpour M, et al. Predictors of syncope in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 2009;32(5):642-7. doi:10.1111/j.1540-8159.2009.02338.x.
124. Seggewiß H, Koljaja-Batzner A, Seggewiß K, Meesmann M. Synkope bei hypertropher (obstruktiver) Kardiomyopathie. Herzschrittmacherther Elektrophysiol. 2018;29(2):178-82.. doi:10.1007/s00399-018-0567-x.
125. Williams L, Frenneaux M. Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment. Europace. 2007;9(9):817-22. doi:10.1093/europace/eum093.
126. Farhad H, Seidelmann SB, Vigneault D, et al. Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. J Cardiovasc Magn Reson. 2017;19(1):107. doi:10.1186/s12968-017-0420-0.
127. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51(8):802-9. doi:10.1016/j.jacc.2007.09.064.
128. Philipson DJ, Rader F, Siegel RJ. Risk factors for atrial fibrillation in hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2019:2047487319828474. doi:10.1177/2047487319828474.
129. Garg L, Gupta M, Sabzwari SRA, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management. Heart Fail Rev. 2019;24(2):189-97. doi:10.1007/s10741-018-9752-6.
130. Killu AM, Park JY, Sara JD, et al. Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy. Europace. 2018;20(1):82-8. doi:10.1093/europace/euw327.
131. Kirchhof P, Benussi S, Kotecha D, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi:10.1093/eurheartj/ehw210.
132. Maron BJ, Rowin EJ, Udelson JE, Maron MS. Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. JACC Heart Fail. 2018;6(5):353-63. doi:10.1016/j.jchf.2017.09.011.
133. Seferović PM, Polovina M, Bauersachs J, et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(5):553-76. doi:10.1002/ejhf.1461.
134. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102(8):858-64. doi:10.1161/01.cir.102.8.858.
135. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-54. doi:10.1016/j.jacc.2015.01.019.
136. Amano Y, Kitamura M, Takayama M, et al. MRI classification of asymmetric septal hypertrophic cardiomyopathy and its relation to the presence of risk factors. Int J Cardiovasc Imaging. 2012;28(8):2019-25. doi:10.1007/s10554-012-0034-4.
137. Geske JB, Ommen SR, Gersh BJ. Hypertrophic Cardiomyopathy: Clinical Update. JACC Heart Fail. 2018;6(5):364-75. doi:10.1016/j.jchf.2018.02.010.
138. Дземешкевич С. Л., Фролова Ю. В., Ким С. Ю. и др. Анатомические и морфологические признаки диффузно-генерализованной формы гипертрофической кардиомиопатии. Российский кардиологический журнал. 2015;(5):58-63. doi:10.15829/1560-4071-2015-5-58-63.
139. Gudkova A, Kostareva A, Sjoberg G, et al. Diagnostic challenge in desmin cardiomyopathy with transformation of clinical phenotypes. Pediatr Cardiol. 2013;34(2):467-70. doi:10.1007/s00246-012-0312-x.
140. Rowin EJ, Maron MS, Chan RH, et al. Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017;120(12):2256-64. doi:10.1016/j.amjcard.2017.08.048.
141. Габрусенко С. А., Сафрыгина Ю. В., Овчинников А. Г. и др. Клинико-гемодинамический статус и сердечные натрийуретические пептиды в плазме больных гипертрофической кардиомиопатией. Кардиологический вестник (Бюллетень РКНПК). 2006;1(2):25-31.
142. Стрельцова А. А., Гудкова А. Я., Костарева А. А. Фибрилляция предсердий при гипертрофической кардиомиопатии: современные аспекты эпидемиологии, факторов риска, патогенеза и фармакотерапии. Consilium Medicum. 2018;20(5):34-9. doi:10.26442/2075-1753_2018.5.34-39.
143. Стрельцова А. А., Гудкова А. Я., Полякова А. А. и др. Полиморфный вариант rs1739843 гена белка теплового шока 7 (HSPB7) и его связь с вариантами клинического течения и исходами у пациентов с гипертрофической кардиомиопатией (результаты 10-летнего наблюдения). Российский кардиологический журнал. 2019;(10):7-15. doi:10.15829/1560-4071-2019-10-7-15.
144. Binder J, Ommen SR, Gersh BJ, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc. 2006;81(4):459-67. doi:10.4065/81.4.459.
145. Elliott P, Spirito P. Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice. Heart. 2008;94(10):1269-75. doi:10.1136/hrt.2008.154385.
146. Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006;92(6):785-91. doi:10.1136/hrt.2005.068577.
147. Kawai C, Sakurai T, Fujiwara H, et al. Hypertrophic obstructive and non-obstructive cardiomyopathy in Japan. Diagnosis of the disease with special reference to endomyocardial catheter biopsy. Eur Heart J. 1983;4, Suppl F:121-5. doi:10.1093/eurheartj/4.suppl_f.121.
148. Kitaoka H, Kuwahara T, Nishida K, et al. Hypertrophic cardiomyopathy with progression from apical hypertrophy to asymmetrical septal hypertrophy: a case report. J Cardiol. 2005;45(4):155-9.
149. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26(7):1699-708. doi:10.1016/0735-1097(95)00390-8.
150. Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(2):301-7. doi:10.1016/s0735-1097(01)01727-2.
151. Thaman R, Gimeno JR, Reith S, et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol. 2004;44(2):398-405. doi:10.1016/j.jacc.2004.01.054.
152. Lancellotti P, Pellikka PA, Budts W, et al. The Clinical Use of Stress Echocardiography in Non-Ischaemic Heart Disease: Recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2017;30(2):101-38. doi:10.1016/j.echo.2016.10.016.
153. Parato VM, Antoncecchi V, Sozzi F, et al.; Italian Chapter of ISCU. Echocardiographic diagnosis of the different phenotypes of hypertrophic cardiomyopathy. Cardiovasc Ultrasound. 2016;14(1):30. doi:10.1186/s12947-016-0072-5.
154. Lambiase PD, Barr C, Theuns DA, et al.; EFFORTLESS Investigators. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35(25):1657-65. doi:10.1093/eurheartj/ehu112.
155. Ponikowski P, Voors AA, Anker SD, et al.; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. doi:10.1002/ejhf.592.
156. Maron BJ, McKenna WJ, Danielson GK, et al.; Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42(9):1687-713. doi:10.1016/s0735-1097(03)00941-0.
157. Barrett MJ, Ayub B, Martinez MW. Cardiac auscultation in sports medicine: strategies to improve clinical care. Curr Sports Med Rep. 2012;11(2):78-84. doi:10.1249/JSR.0b013e318249c0ff.
158. Cantwell JD. Preparticipation physical evaluation: getting to the heart of the matter. Med Sci Sports Exerc. 1998;30(10 Suppl):S341-4. doi:10.1097/00005768-199810001-00001.
159. Efthimiadis GK, Parcharidou D, Pagourelias ED, et al. Prevalence and clinical outcomes of incidentally diagnosed hypertrophic cardiomyopathy. Am J Cardiol. 2010;105(10):1445-50. doi:10.1016/j.amjcard.2009.12.066.
160. Harmon KG, Zigman M, Drezner JA. The effectiveness of screening history, physical exam, and ECG to detect potentially lethal cardiac disorders in athletes: a systematic review/meta-analysis. J Electrocardiol. 2015;48(3):329-38. doi:10.1016/j.jelectrocard.2015.02.001.
161. Raviele A, Giada F, Bergfeldt L, et al.; European Heart Rhythm Association. Management of patients with palpitations: a position paper from the European Heart Rhythm Association. Europace. 2011;13(7):920-34. doi:10.1093/europace/eur130.
162. Attenhofer Jost CH, Turina J, Mayer K, et al. Echocardiography in the evaluation of systolic murmurs of unknown cause. Am J Med. 2000;108(8):614-20. doi:10.1016/s0002-9343(00)00361-2.
163. Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(19):1448-58. doi:10.1093/eurheartj/ehs397.
164. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520-8. doi:10.1093/eurheartj/ehs123.
165. Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis. 2008;3:13. doi:10.1186/1750-1172-3-13.
166. Scaglia F, Towbin JA, Craigen WJ, et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics. 2004;114(4):925-31. doi:10.1542/peds.2004-0718.
167. Pagourelias ED, Efthimiadis GK, Kouidi E, et al. Efficacy of various "classic" echocardiographic and laboratory indices in distinguishing the "gray zone" between athlete's heart and hypertrophic cardiomyopathy: a pilot study. Echocardiography. 2013;30(2):131-9. doi:10.1111/echo.12014.
168. Coutu M, Perrault LP, White M, et al. Cardiac transplantation for hypertrophic cardiomyopathy: a valid therapeutic option. J Heart Lung Transplant. 2004;23(4):413-7. doi:10.1016/S1053-2498(03)00225-0.
169. Zhang C, Huang X, Li J. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role? Blood Rev. 2017;31(4):261-70. doi:10.1016/j.blre.2017.03.002.
170. Ingles J, Burns C, Bagnall RD, et al. Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. Circ Cardiovasc Genet. 2017;10(2):e001620. doi:10.1161/CIRCGENETICS.116.001620.
171. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation. 1995;91(5):1596-601. doi:10.1161/01.cir.91.5.1596.
172. Young L, Smedira NG, Tower-Rader A, et al. Hypertrophic cardiomyopathy: A complex disease. Cleve Clin J Med. 2018;85(5):399-411. doi:10.3949/ccjm.85a.17076.
173. Efthimiadis GK, Pagourelias ED, Gossios T, Zegkos T. Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives. World J Cardiol. 2014;6(2):26-37. doi:10.4330/wjc.v6.i2.26.
174. Hershberger RE, Givertz MM, Ho CY, et al. Genetic Evaluation of Cardiomyopathy – A Heart Failure Society of America Practice Guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004.
175. Efthimiadis GK, Pagourelias E, Zegkos T, et al. An Overview of Pharmacotherapy in Hypertrophic Cardiomyopathy: Current Speculations and Clinical Perspectives. Rev Cardiovasc Med. 2016;17(3-4):115-23.
176. Fananapazir L, Tracy CM, Leon MB, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation. 1989;80(5):1259-68. doi:10.1161/01.cir.80.5.1259.
177. Kelly BS, Mattu A, Brady WJ. Hypertrophic cardiomyopathy: electrocardiographic manifestations and other important considerations for the emergency physician. Am J Emerg Med. 2007;25(1):72-9. doi:10.1016/j.ajem.2006.04.017.
178. McLeod CJ, Ackerman MJ, Nishimura RA, et al. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J Am Coll Cardiol. 2009;54(3):229-33. doi:10.1016/j.jacc.2009.02.071.
179. Wilke I, Witzel K, Münch J, et al. High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device. J Cardiovasc Electrophysiol. 2016;27(7):779-84. doi:10.1111/jce.12982.
180. Хирманов В. Н., Трешкур Е. В., Тюрина Т. В. и др. Электрокардиографические методы в диагностике, выборе метода и тактики лечения гипертрофической кардиомиопатии. Progress in Biomedical Research: Сборник статей. СПб, 1997. Т. 2 (1), сс. 7-21.
181. O'Mahony C, Jichi F, Pavlou M, et al.; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35(30):2010-20. doi:10.1093/eurheartj/eht439.
182. Wasfy MM, Weiner RB. Differentiating the athlete's heart from hypertrophic cardiomyopathy. Curr Opin Cardiol. 2015;30(5):500-5. doi:10.1097/HCO.0000000000000203.
183. Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997;126(8):615-20. doi:10.7326/0003-4819-126-8-199704150-00005.
184. Guttmann OP, Rahman MS, O'Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014;100(6):465-72. doi:10.1136/heartjnl-2013-304276.
185. Task Force members, Brignole M, Vardas P, Hoffman E, et al.; EHRA Scientific Documents Committee. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace. 2009;11(5):671-87. doi:10.1093/europace/eup097. Erratum in: Europace. 2009;11(6):836.
186. Frangini PA, Cecchin F, Jordao L, et al. How revealing are insertable loop recorders in pediatrics? Pacing Clin Electrophysiol. 2008;31(3):338-43. doi:10.1111/j.1540-8159.2008.00995.x.
187. Solano A, Menozzi C, Maggi R, et al. Incidence, diagnostic yield and safety of the implantable loop-recorder to detect the mechanism of syncope in patients with and without structural heart disease. Eur Heart J. 2004;25(13):1116-9. doi:10.1016/j.ehj.2004.05.013.
188. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43(12):2260-4. doi:10.1016/j.jacc.2004.03.035.
189. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56(11):867-74. doi:10.1016/j.jacc.2010.05.010.
190. Pernat A, Pohar B, Horvat M. Heart conduction disturbances and cardiovascular collapse after disopyramide and low-dose metoprolol in a patient with hypertrophic obstructive cardiomyopathy. J Electrocardiol. 1997;30(4):341-4. doi:10.1016/s0022-0736(97)80048-9.
191. Cerqueira MD, Weissman NJ, Dilsizian V, et al.; American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105(4):539-42. doi:10.1161/hc0402.102975.
192. Flachskampf FA, Badano L, Daniel WG, et al. Recommendations for transoesophageal echocardiography: update 2010. Eur J Echocardiogr. 2010;11(7):557-76. doi:10.1093/ejechocard/jeq057. Erratum in: Eur J Echocardiogr. 2011;12(3):255.
193. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-70. doi:10.1093/ehjci/jev014. Erratum in: Eur Heart J Cardiovasc Imaging. 2016;17(4):412. Erratum in: Eur Heart J Cardiovasc Imaging. 2016;17(9):969.
194. Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32(1):1-64. doi:10.1016/j.echo.2018.06.004.
195. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10(2):165-93. doi:10.1093/ejechocard/jep007.
196. Senior R, Becher H, Monaghan M, et al. Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography. Eur J Echocardiogr. 2009;10(2):194-212. doi:10.1093/ejechocard/jep005.
197. Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol. 2003;42(5):882-8. doi:10.1016/s0735-1097(03)00855-6.
198. Maron BJ, Rowin EJ, Maron MS, Braunwald E. Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored … Until Now. Am J Med. 2017;130(2):119-23. doi:10.1016/j.amjmed.2016.09.015.
199. Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232-9. doi:10.1161/CIRCULATIONAHA.106.644682.
200. Spirito P, Autore C, Formisano F, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014;113(9):1550-5. doi:10.1016/j.amjcard.2014.01.435.
201. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778-85. doi:10.1056/NEJM200006153422403.
202. Belenkie I, MacDonald RP, Smith ER. Localized septal hypertrophy: part of the spectrum of hypertrophic cardiomyopathy or an incidental echocardiographic finding? Am Heart J. 1988;115(2):385-90. doi:10.1016/0002-8703(88)90486-3.
203. Gardin J, Palabrica T, Dubria S, et al. Localized basal ventricular septal hypertrophy - prevalence, functional and clinical correlates in a population referred for echocardiography. Am J Noninvas Card. 1992;6(1):5-8. doi:10.1159/000470319.
204. Losi MA, Nistri S, Galderisi M, et al.; Working Group of Echocardiography of the Italian Society of Cardiology. Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound. 2010;8:7. doi:10.1186/1476-7120-8-7.
205. Alvares RF, Goodwin JF. Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. Br Heart J. 1982;48(3):204-12. doi:10.1136/hrt.48.3.204.
206. Dimitrow PP, Bober M, Michałowska J, Sorysz D. Left ventricular outflow tract gradient provoked by upright position or exercise in treated patients with hypertrophic cardiomyopathy without obstruction at rest. Echocardiography. 2009;26(5):513-20. doi:10.1111/j.1540-8175.2008.00851.x.
207. Elliott P, Gimeno J, Tomé M, McKenna W. Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. Eur Heart J. 2006;27(24):3073; author reply 3073-4. doi:10.1093/eurheartj/ehl383.
208. Nistri S, Olivotto I, Maron MS, et al. Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. Am J Cardiol. 2010;106(9):1301-6. doi:10.1016/j.amjcard.2010.06.057.
209. Olivotto I, Montereggi A, Mazzuoli F, Cecchi F. Clinical utility and safety of exercise testing in patients with hypertrophic cardiomyopathy. G Ital Cardiol. 1999;29(1):11-9.
210. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96(9):2987-91. doi:10.1161/01.cir.96.9.2987.
211. Tower-Rader A, Betancor J, Lever HM, Desai MY. A Comprehensive Review of Stress Testing in Hypertrophic Cardiomyopathy: Assessment of Functional Capacity, Identification of Prognostic Indicators, and Detection of Coronary Artery Disease. J Am Soc Echocardiogr. 2017;30(9):829-44. doi:10.1016/j.echo.2017.05.017.
212. Yalçin F, Muderrisoglu H, Korkmaz ME, et al. The effect of dobutamine stress on left ventricular outflow tract gradients in hypertensive patients with basal septal hypertrophy. Angiology. 2004;55(3):295-301. doi:10.1177/000331970405500309.
213. Mestres CA, Bartel T, Sorgente A, et al. Hypertrophic obstructive cardiomyopathy: what, when, why, for whom? Eur J Cardiothorac Surg. 2018;53(4):700-7. doi:10.1093/ejcts/ezy020.
214. Mickelsen S, Bathina M, Hsu P, et al. Doppler evaluation of the descending aorta in patients with hypertrophic cardiomyopathy: potential for assessing the functional significance of outflow tract gradients and for optimizing pacemaker function. J Interv Card Electrophysiol. 2004;11(1):47-53. doi:10.1023/B:JICE.0000035929.84238.2f.
215. Tezuka A, Higo K, Nakamukae Y, et al. Bisoprolol Successfully Improved the Intraventricular Pressure Gradient in a Patient with Midventricular Obstructive Hypertrophic Cardiomyopathy with an Apex Aneurysm due to Apical Myocardial Damage. Intern Med. 2019;58(4):535-9. doi:10.2169/internalmedicine.0997-18.
216. Cardim N, Galderisi M, Edvardsen T, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015;16(3):280. doi:10.1093/ehjci/jeu291.
217. Kim MS, Klein AJ, Groves BM, et al. Left ventricular outflow tract obstruction in the presence of asymmetric septal hypertrophy and accessory mitral valve tissue treated with alcohol septal ablation. Eur J Echocardiogr. 2008;9(5):720-4. doi:10.1093/ejechocard/jen152.
218. Monakier D, Woo A, Puri T, et al. Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2004;94(12):1515-22. doi:10.1016/j.amjcard.2004.08.030.
219. Wallace EL, Thompson JJ, Faulkner MW, et al. Septal perforator anatomy and variability of perfusion bed by myocardial contrast echocardiography: a study of hypertrophic cardiomyopathy patients undergoing alcohol septal ablation. J Interv Cardiol. 2013;26(6):604-12. doi:10.1111/joic.12068.
220. Grigg LE, Wigle ED, Williams WG, et al. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol. 1992;20(1):42-52. doi:10.1016/0735-1097(92)90135-a.
221. Marwick TH, Stewart WJ, Lever HM, et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;20(5):1066-72. doi:10.1016/0735-1097(92)90359-u.
222. Oki T, Fukuda N, Iuchi A, et al. Transesophageal echocardiographic evaluation of mitral regurgitation in hypertrophic cardiomyopathy: contributions of eccentric left ventricular hypertrophy and related abnormalities of the mitral complex. J Am Soc Echocardiogr. 1995;8(4):503-10. doi:10.1016/s0894-7317(05)80338-4.
223. Yu EH, Omran AS, Wigle ED, et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol. 2000;36(7):2219-25. doi:10.1016/s0735-1097(00)01019-6.
224. McIntosh CL, Maron BJ, Cannon RO 3rd, Klues HG. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation. 1992;86(5 Suppl):II60-7.
225. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5(4):370-7. doi:10.1016/j.jcmg.2011.11.021.
226. Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart. 2004;90(6):645-9. doi:10.1136/hrt.2003.014969.
227. Olivotto I, Maron MS, Autore C, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52(7):559-66. doi:10.1016/j.jacc.2008.04.047.
228. Prinz C, Schwarz M, Ilic I, et al. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy. Can J Cardiol. 2013;29(3):358-63. doi:10.1016/j.cjca.2012.05.004.
229. Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112(6):855-61. doi:10.1161/CIRCULATIONAHA.104.507723.
230. Rudolph A, Abdel-Aty H, Bohl S, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol. 2009;53(3):284-91. doi:10.1016/j.jacc.2008.08.064.
231. Webb J, Fovargue L, Tøndel K, et al. The Emerging Role of Cardiac Magnetic Resonance Imaging in the Evaluation of Patients with HFpEF. Curr Heart Fail Rep. 2018;15(1):1-9. doi:10.1007/s11897-018-0372-1.
232. Albano BB, Fadreguilan EC, Chua JM, et al. Treating a Structural Heart Disease Using a Non-structural Approach: Role of Cardiac Pacing in Hypertrophic Cardiomyopathy. Cardiol Res. 2017;8(1):20-5. doi:10.14740/cr512w.
233. Puntmann VO, Gebker R, Duckett S, et al. Left ventricular chamber dimensions and wall thickness by cardiovascular magnetic resonance: comparison with transthoracic echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14(3):240-6. doi:10.1093/ehjci/jes145.
234. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047-60. doi:10.1161/CIRCULATIONAHA.104.489187.
235. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-12. doi:10.1161/CIRCULATIONAHA.116.021612.
236. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):155-64. doi:10.1016/j.jcmg.2009.09.023.
237. Todiere G, Aquaro GD, Piaggi P, et al. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2012;60(10):922-9. doi:10.1016/j.jacc.2012.03.076.
238. O'Hanlon R, Assomull RG, Prasad SK. Use of cardiovascular magnetic resonance for diagnosis and management in hypertrophic cardiomyopathy. Curr Cardiol Rep. 2007;9(1):51-6. doi:10.1007/s11886-007-0010-0.
239. Patel P, Dhillon A, Popovic ZB, et al. Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy: Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography. Circ Cardiovasc Imaging. 2015;8(7):e003132. doi:10.1161/CIRCIMAGING.115.003132.
240. Gruner C, Chan RH, Crean A, et al. Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2706-13. doi:10.1093/eurheartj/ehu154.
241. Brouwer WP, Germans T, Head MC, et al. Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers. Eur Heart J Cardiovasc Imaging. 2012;13(4):292-7. doi:10.1093/ehjci/jes005.
242. Schroeder S, Achenbach S, Bengel F, et al.; Working Group Nuclear Cardiology and Cardiac CT; European Society of Cardiology; European Council of Nuclear Cardiology. Cardiac computed tomography: indications, applications, limitations, and training requirements: report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. Eur Heart J. 2008;29(4):531-56. doi:10.1093/eurheartj/ehm544.
243. Esposito A, Colantoni C, De Cobelli F, et al. Multidetector computed tomography for coronary stents imaging: high-voltage (140-kVp) prospective ECG-triggered versus standard-voltage (120-kVp) retrospective ECG-gated helical scanning. J Comput Assist Tomogr. 2013;37(3):395-401. doi:10.1097/RCT.0b013e3182873559.
244. Shiozaki AA, Senra T, Arteaga E, et al. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. J Cardiovasc Comput Tomogr. 2013;7(3):173-81. doi:10.1016/j.jcct.2013.04.002.
245. Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38(3):470-8. doi:10.1007/s00259-010-1642-7.
246. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659-70. doi:10.1016/j.jcmg.2011.03.016.
247. Katayama M, Panse PM, Kendall CB, et al. Left Ventricular Septal Hypertrophy in Elderly Patients With Aortic Stenosis. J Ultrasound Med. 2018;37(1):217-24. doi:10.1002/jum.14320.
248. Mitsutake R, Miura S, Sako H, et al. Usefulness of multi-detector row computed tomography for the management of percutaneous transluminal septal myocardial ablation in patient with hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2008;129(2):e61-3. doi:10.1016/j.ijcard.2007.06.132.
249. Scalone G, Niccoli G, Crea F. Editor's Choice – Pathophysiology, diagnosis and management of MINOCA: an update. Eur Heart J Acute Cardiovasc Care. 2019;8(1):54-62. doi:10.1177/2048872618782414.
250. Okayama S, Uemura S, Soeda T, et al. Role of cardiac computed tomography in planning and evaluating percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. J Cardiovasc Comput Tomogr. 2010;4(1):62-5. doi:10.1016/j.jcct.2009.10.004.
251. Villa AD, Sammut E, Zarinabad N, et al. Microvascular ischemia in hypertrophic cardiomyopathy: new insights from high-resolution combined quantification of perfusion and late gadolinium enhancement. J Cardiovasc Magn Reson. 2016;18:4. doi:10.1186/s12968-016-0223-8.
252. Chen JM, Levin HR, Michler RE, et al. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg. 1997;114(4):627-34. doi:10.1016/S0022-5223(97)70053-9.
253. Kato TS, Takayama H, Yoshizawa S, et al. Cardiac transplantation in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012;110(4):568-74. doi:10.1016/j.amjcard.2012.04.030.
254. Lindelöw B, Andersson B, Waagstein F, Bergh CH. High and low pulmonary vascular resistance in heart transplant candidates. A 5-year follow-up after heart transplantation shows continuous reduction in resistance and no difference in complication rate. Eur Heart J. 1999;20(2):148-56. doi:10.1053/euhj.1998.1155.
255. Maron MS, Kalsmith BM, Udelson JE, et al. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3(5):574-9. doi:10.1161/CIRCHEARTFAILURE.109.922872.
256. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates – 2006. J Heart Lung Transplant. 2006;25(9):1024-42. doi:10.1016/j.healun.2006.06.008.
257. Torres MF, Perez-Villa F. Heart transplantation in patients with hypertrophic cardiomyopathy. Glob Cardiol Sci Pract. 2018;2018(3):32. doi:10.21542/gcsp.2018.32.
258. Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al.; European Society of Cardiology Committee, NASPE-Heart Rhythm Society. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias – executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003;42(8):1493-531. doi:10.1016/j.jacc.2003.08.013.
259. Бокерия Л. А., Берсенёва М. И., Маленков Д. А. Аритмогенные осложнения гипертрофической кардиомиопатии. Анналы аритмологии. 2010;7(3):62-9.
260. Muresan L, Cismaru G, Martins RP, et al. Recommendations for the use of electrophysiological study: Update 2018. Hellenic J Cardiol. 2019;60(2):82-100. doi:10.1016/j.hjc.2018.09.002.
261. Wang W, Lian Z, Rowin EJ, et al. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol. 2017;10(3):e004604. doi:10.1161/CIRCEP.116.004604.
262. Inada K, Seiler J, Roberts-Thomson KC, et al. Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011;22(1):41-8. doi:10.1111/j.1540-8167.2010.01875.x.
263. Lim KK, Maron BJ, Knight BP. Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm. J Cardiovasc Electrophysiol. 2009;20(4):445-7. doi:10.1111/j.1540-8167.2008.01366.x.
264. Refaat MM, Hotait M, Tseng ZH. Utility of the exercise electrocardiogram testing in sudden cardiac death risk stratification. Ann Noninvasive Electrocardiol. 2014;19(4):311-8. doi:10.1111/anec.12191.
265. Yi G, Poloniecki J, Dickie S, et al. Can the assessment of dynamic QT dispersion on exercise electrocardiogram predict sudden cardiac death in hypertrophic cardiomyopathy? Pacing Clin Electrophysiol. 2000;23(11 Pt 2):1953-6. doi:10.1111/j.1540-8159.2000.tb07060.x.
266. Nistri S, Olivotto I, Maron MS, et al. β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012;110(5):715-9. doi:10.1016/j.amjcard.2012.04.051.
267. Rowin EJ, Maron BJ, Olivotto I, Maron MS. Role of Exercise Testing in Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging. 2017;10(11):1374-86. doi:10.1016/j.jcmg.2017.07.016.
268. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83(3):778-86. doi:10.1161/01.cir.83.3.778.
269. Sharma S, Elliott P, Whyte G, et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol. 2000;86(2):162-8. doi:10.1016/s0002-9149(00)00854-7.
270. Колоскова Н. Н., Шаталов К. В., Бокерия Л. А. Определение пикового потребления кислорода: клиническое использование и перспективы. Креативная кардиология. 2014;(2):20-8.
271. Coats CJ, Rantell K, Bartnik A, et al. Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. Circ Heart Fail. 2015;8(6):1022-31. doi:10.1161/CIRCHEARTFAILURE.114.002248.
272. Arena R, Owens DS, Arevalo J, et al. Ventilatory efficiency and resting hemodynamics in hypertrophic cardiomyopathy. Med Sci Sports Exerc. 2008;40(5):799-805. doi:10.1249/MSS.0b013e31816459a1.
273. Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33(7):2044-51. doi:10.1016/s0735-1097(99)00094-7.
274. Diodati JG, Schenke WH, Waclawiw MA, et al. Predictors of exercise benefit after operative relief of left ventricular outflow obstruction by the myotomy-myectomy procedure in hypertrophic cardiomyopathy. Am J Cardiol. 1992;69(19):1617-22. doi:10.1016/0002-9149(92)90713-9.
275. Bennett MK, Gilotra NA, Harrington C, et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. Circ Heart Fail. 2013;6(4):676-84. doi:10.1161/CIRCHEARTFAILURE.112.000087.
276. Schönland SO, Hegenbart U, Bochtler T, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood. 2012;119(2):488-93. doi:10.1182/blood-2011-06-358507.
277. Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. 2017;38(24):1905-8. doi:10.1093/eurheartj/ehx047.
278. Крылова Н. С., Хашиева Ф. М., Демкина А. Е. и др. Гипертрофическая кардиомиопатия и артериальная гипертензия: возможно ли сочетание? Сердце: журнал для практикующих врачей. 2015;14(3):164-9.
279. Полякова А. А., Гудкова А. Я., Крутиков А. Н. и др. Гипертрофическая кардиомиопатия в старшей возрастной группе: влияние факторов кардиометаболического риска и полиморфизма гена MADD. Артериальная гипертензия. 2018;24(1):29-40. doi:10.18705/1607-419X-2018-24-1-29-40.
280. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008;88(2):389-419. doi:10.1152/physrev.00017.2007.
281. Ommen SR, Lopez-Jimenez F. Obesity and hypertrophic cardiomyopathy: chickens, eggs, and causality: clinical skills remain the key to caring for patients. J Am Coll Cardiol. 2013;62(5):458-9. doi:10.1016/j.jacc.2013.03.063.
282. Olivotto I, Maron BJ, Tomberli B, et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62(5):449-57. doi:10.1016/j.jacc.2013.03.062.
283. van Straten AH, Soliman Hamad MA, Peels KC, et al. Increased septum wall thickness in patients undergoing aortic valve replacement predicts worse late survival. Ann Thorac Surg. 2012;94(1):66-71. doi:10.1016/j.athoracsur.2012.03.027.
284. Di Tommaso L, Stassano P, Mannacio V, et al. Asymmetric septal hypertrophy in patients with severe aortic stenosis: the usefulness of associated septal myectomy. J Thorac Cardiovasc Surg. 2013;145(1):171-5. doi:10.1016/j.jtcvs.2011.10.096.
285. Dweck MR, Joshi S, Murigu T, et al. Left ventricular remodeling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14(1):50. doi:10.1186/1532-429X-14-50.
286. Maron BJ, Edwards JE, Epstein SE. Disproportionate ventricular thickening in patients with systemic hypertension. Chest. 1978;73(4):466-70. doi:10.1378/chest.73.4.466.
287. Rodrigues JC, Amadu AM, Dastidar AG, et al. Prevalence and predictors of asymmetric hypertensive heart disease: insights from cardiac and aortic function with cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging. 2016;17(12):1405-13. doi:10.1093/ehjci/jev329.
288. Tuseth N, Cramariuc D, Rieck AE, et al. Asymmetric septal hypertrophy – marker of hypertension in aortic stenosis (a SEAS substudy). Blood Press. 2010;19(3):140-4. doi:10.3109/08037051.2010.481816.
289. Shapiro LM, Howat AP, Crean PA, Westgate CJ. An echocardiographic study of localized subaortic hypertrophy. Eur Heart J. 1986;7(2):127-32. doi:10.1093/oxfordjournals.eurheartj.a062034.
290. Raissuni Z, Doghmi N, Mousseaux E, et al. Hypertrophic cardiomyopathy mimicking STEMI: The role of cardiac magnetic resonance imaging in the detection of microvascular coronary dysfunction. Diagn Interv Imaging. 2014;95(11):1111-2. doi:10.1016/j.diii.2013.12.020.
291. Timmer SA, Knaapen P. Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopathy: insights from positron emission tomography. Eur Heart J Cardiovasc Imaging. 2013;14(2):95-101. doi:10.1093/ehjci/jes242.
292. Zhang YD, Li M, Qi L, et al. Hypertrophic cardiomyopathy: Cardiac structural and microvascular abnormalities as evaluated with multi-parametric MRI. Eur J Radiol. 2015;84(8):1480-6. doi:10.1016/j.ejrad.2015.04.028.
293. Gutiérrez-Barrios A, Camacho-Jurado F, Díaz-Retamino E, et al. Invasive assessment of coronary microvascular dysfunction in hypertrophic cardiomyopathy: the index of microvascular resistance. Cardiovasc Revasc Med. 2015;16(7):426-8. doi:10.1016/j.carrev.2015.06.008.
294. Ismail TF, Hsu LY, Greve AM, et al. Coronary microvascular ischemia in hypertrophic cardiomyopathy - a pixel-wise quantitative cardiovascular magnetic resonance perfusion study. J Cardiovasc Magn Reson. 2014;16(1):49. doi:10.1186/s12968-014-0049-1.
295. Olivotto I, Girolami F, Sciagrà R, et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol. 2011;58(8):839-48. doi:10.1016/j.jacc.2011.05.018.
296. Zipes DP, Camm AJ, Borggrefe M, et al.; American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(10):e385-484. doi:10.1161/CIRCULATIONAHA.106.178233.
297. Basavarajaiah S, Wilson M, Whyte G, et al. Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J Am Coll Cardiol. 2008;51(10):1033-9. doi:10.1016/j.jacc.2007.10.055.
298. Malhotra A, Sharma S. Hypertrophic Cardiomyopathy in Athletes. Eur Cardiol. 2017;12(2):80-2. doi:10.15420/ecr.2017:12:1.
299. Pelliccia A, Solberg EE, Papadakis M, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2019;40(1):19-33. doi:10.1093/eurheartj/ehy730.
300. Liebregts M, Faber L, Jensen MK, et al. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation. Europace. 2018;20(FI2):f198-f203. doi:10.1093/europace/eux251.
301. Spoladore R, Maron MS, D'Amato R, et al. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J. 2012;33(14):1724-33. doi:10.1093/eurheartj/ehs150.
302. Toshima H, Koga Y, Nagata H, et al. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. Jpn Heart J. 1986;27(5):701-15. doi:10.1536/ihj.27.701.
303. Galve E, Sambola A, Saldaña G, et al. Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study. Heart. 2010;96(5):352-6. doi:10.1136/hrt.2008.158915.
304. Gentry JL 3rd, Mentz RJ, Hurdle M, Wang A. Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME). J Am Coll Cardiol. 2016;68(16):1815-7. doi:10.1016/j.jacc.2016.07.758.
305. Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J. 1997(8):1249-56. doi:10.1093/oxfordjournals.eurheartj.a015435.
306. Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999;99(22):2927-33. doi:10.1161/01.cir.99.22.2927.
307. Maron MS, Chan RH, Kapur NK, et al. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018;131(7):837-41. doi:10.1016/j.amjmed.2018.02.025.
308. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol. 1997;29(2):435-41. doi:10.1016/s0735-1097(96)00473-1.
309. Olivotto I, Camici PG, Merlini PA, et al. Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study. Circ Heart Fail. 2018;11(1):e004124. doi:10.1161/CIRCHEARTFAILURE.117.004124.
310. Slade AK, Sadoul N, Shapiro L, et al. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart. 1996;75(1):44-9. doi:10.1136/hrt.75.1.44.
311. Jung H, Yang PS, Jang E, et al. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study. Chest. 2019;155(2):354-63. doi:10.1016/j.chest.2018.11.009.
312. Zhou Y, He W, Zhou Y, Zhu W. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis. J Thromb Thrombolysis. 2020;50(2):311-7. doi:10.1007/s11239-019-02008-3.
313. Rujirachun P, Charoenngam N, Wattanachayakul P, et al. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis. Acta Cardiol. 2020;75(8):724-31. doi:10.1080/00015385.2019.1668113.
314. Patten M, Pecha S, Aydin A. Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management. J Atr Fibrillation. 2018;10(5):1556. doi:10.4022/jafib.1556.
315. Dearani JA, Ommen SR, Gersh BJ, et al. Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy–the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med. 2007;4(9):503-12. doi:10.1038/ncpcardio0965.
316. Leonardi RA, Kransdorf EP, Simel DL, Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010;3(2):97-104. doi:10.1161/CIRCINTERVENTIONS.109.916676.
317. Zeng Z, Wang F, Dou X, et al. Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy – a meta analysis. Int J Cardiol. 2006;112(1):80-4. doi:10.1016/j.ijcard.2005.10.009.
318. Afanasyev AV, Bogachev-Prokophiev AV, Ovcharov MA, et al. Single-Centre Experience of Surgical Myectomy for Hypertrophic Obstructive Cardiomyopathy. Heart Lung Circ. 2020;29(6):949-55. doi:10.1016/j.hlc.2019.07.009.
319. Veselka J, Faber L, Liebregts M, et al. Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis. Eur Heart J. 2019;40(21):1681-7. doi:10.1093/eurheartj/ehz110.
320. Майстренко А. Д., Гурщенков А. В., Паскарь Н. С. и др. Современное состояние проблемы хирургического лечения гипертрофической обструктивной кардиомиопатии. Вестник хирургии имени И.И. Грекова. 2013;172(2):082-7. doi:10.24884/0042-4625-2013-172-2-082-087.
321. Хитрова М. Э., Бокерия Л. А., Берсенева М. И. и др. Метаанализ результатов хирургического лечения гипертрофической обструктивной кардиомиопатии. Креативная кардиология. 2017;11(4):337-47. doi:10.24022/1997-3187-2017-11-4-337-347.
322. Богданов Д. В., Шапошник И. И. Варианты клинического течения, исходы и прогноз гипертрофической необструктивной кардиомиопатии – результаты длительного наблюдения. Российский кардиологический журнал. 2019;(11):48-54. doi:10.15829/1560-4071-2019-11-48-54.
323. Vriesendorp PA, Schinkel AF, Liebregts M, et al. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8(4):829-35. doi:10.1161/CIRCEP.114.002553.
324. Falk V, Baumgartner H, Bax JJ, et al.; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg. 2017;52(4):616-64. doi:10.1093/ejcts/ezx324. Erratum in: Eur J Cardiothorac Surg. 2017;52(4):832.
325. Lourenço AP, Leite-Moreira AF, Balligand JL, et al. An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail. 2018;20(2):216-27. doi:10.1002/ejhf.1059.
326. Мареев В. Ю., Фомин И. В., Агеев Ф. Т. и др. Клинические рекомендации ОССН - РКО - РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158. doi:10.18087/cardio.2475.
327. Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.
328. Гудкова А. Я., Стрельцова А. А., Костарева А. А. Гипертрофическая кардиомиопатия: современные возможности фармакологических подходов к лечению. Терапевтический архив. 2019;91(9):129-36. doi:10.26442/00403660.2019.09.000137.
329. Ammirati E, Contri R, Coppini R, et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016;18(9):1106-18. doi:10.1002/ejhf.541.
330. Spicer RL, Rocchini AP, Crowley DC, et al. Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy. Circulation. 1983;67(2):413-20. doi:10.1161/01.cir.67.2.413.
331. Flamm MD, Harrison DC, Hancock EW. Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol. Circulation. 1968;38(5):846-58. doi:10.1161/01.cir.38.5.846.
332. Sherrid MV. Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice. Curr Cardiol Rev. 2016;12(1):52-65. doi:10.2174/1573403x1201160126125403.
333. Sherrid MV, Gunsburg D, Sharma A. Medical treatment of hypertrophic cardiomyopathy. Curr Cardiol Rep. 2000;2(2):148-53. doi:10.1007/s11886-000-0012-7.
334. Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251-8. doi:10.1016/j.jacc.2005.01.012.
335. Sherrid MV, Shetty A, Winson G, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. Circ Heart Fail. 2013;6(4):694-702. doi:10.1161/CIRCHEARTFAILURE.112.000122.
336. Adelman AG, Shah PM, Gramiak R, Wigle ED. Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J. 1970;32(6):804-11. doi:10.1136/hrt.32.6.804.
337. Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation. 1985;72(4):853-64. doi:10.1161/01.cir.72.4.853.
338. Bonow RO, Rosing DR, Epstein SE. The acute and chronic effects of verapamil on left ventricular function in patients with hypertrophic cardiomyopathy. Eur Heart J. 1983;4, Suppl F:57-65. doi:10.1093/eurheartj/4.suppl_f.57.
339. Gistri R, Cecchi F, Choudhury L, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol. 1994;74(4):363-8. doi:10.1016/0002-9149(94)90404-9.
340. Rosing DR, Condit JR, Maron BJ, et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am J Cardiol. 1981;48(3):545-53. doi:10.1016/0002-9149(81)90086-2.
341. Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation. 1979;60(6):1208-13. doi:10.1161/01.cir.60.6.1208.
342. Said SM, Schaff HV, Abel MD, Dearani JA. Transapical approach for apical myectomy and relief of midventricular obstruction in hypertrophic cardiomyopathy. J Card Surg. 2012;27(4):443-8. doi:10.1111/j.1540-8191.2012.01475.x.
343. Shah A, Duncan K, Winson G, et al. Severe symptoms in mid and apical hypertrophic cardiomyopathy. Echocardiography. 2009;26(8):922-33. doi:10.1111/j.1540-8175.2009.00905.x.
344. Maron MS, Rowin EJ, Olivotto I, et al. Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2016;67(12):1399-409. doi:10.1016/j.jacc.2016.01.023.
345. McMurray JJ, Adamopoulos S, Anker SD, et al.; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-847. doi:10.1093/eurheartj/ehs104. Erratum in: Eur Heart J. 2013;34(2):158.
346. Сафрыгина Ю. В., Габрусенко С. А., Овчинников А. Г. и др. Сердечные натрийуретические пептиды в плазме больных гипертрофической кардиомиопатией. Кардиология. 2007;47(5):50-7.
347. Braunwald E, Lambrew CT, Rockoff SD, et al. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation. 1964;30:Suppl 4:3-119. doi:10.1161/01.cir.29.5s4.iv-3.
348. Okeie K, Shimizu M, Yoshio H, et al. Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2000;36(3):856-63. doi:10.1016/s0735-1097(00)00818-4.
349. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981;64(3):437-41. doi:10.1161/01.cir.64.3.437.
350. Shimada YJ, Passeri JJ, Baggish AL, et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2013;1(6):480-7. doi:10.1016/j.jchf.2013.09.001.
351. Udelson JE, Bonow RO, O'Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1989;79(5):1052-60. doi:10.1161/01.cir.79.5.1052.
352. Wilmshurst PT, Thompson DS, Juul SM, et al. Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. Br Heart J. 1986;56(6):544-53. doi:10.1136/hrt.56.6.544.
353. Argulian E, Messerli FH, Aziz EF, et al. Antihypertensive therapy in hypertrophic cardiomyopathy. Am J Cardiol. 2013;111(7):1040-5. doi:10.1016/j.amjcard.2012.12.026.
354. Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail. 2012;5(4):535-46. doi:10.1161/CIRCHEARTFAILURE.112.967026.
355. Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol. 1990;15(6):1279-85. doi:10.1016/s0735-1097(10)80014-2.
356. Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517-24. doi:10.1161/hc4601.097997.
357. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92(4):785-9. doi:10.1161/01.cir.92.4.785.
358. Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines-CPG; Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385-413. doi:10.1093/europace/eus305.
359. Camm CF, Camm AJ. Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy. Arrhythm Electrophysiol Rev. 2017;6(2):63-8. doi:10.15420/aer.2017.4.2.
360. Di Cori A, Lilli A, Zucchelli G, Zaca V. Role of cardiac electronic implantable device in the stratification and management of embolic risk of silent atrial fibrillation: are all atrial fibrillations created equal? Expert Rev Cardiovasc Ther. 2018;16(3):175-81. doi:10.1080/14779072.2018.1438267.
361. van Velzen HG, Theuns DA, Yap SC, et al. Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2017;119(1):100-5. doi:10.1016/j.amjcard.2016.08.092.
362. Brambatti M, Connolly SJ, Gold MR, et al.; ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094-9. doi:10.1161/CIRCULATIONAHA.113.007825.
363. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429. doi:10.1093/eurheartj/ehq278. Erratum in: Eur Heart J. 2011;32(9):1172.
364. Miller CAS, Maron MS, Estes NAM III, et al. Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol. 2019;123(11):1859-62. doi:10.1016/j.amjcard.2019.02.051.
365. Schaufelberger M. Cardiomyopathy and pregnancy. Heart. 2019;105(20):1543-51. doi:10.1136/heartjnl-2018-313476.
366. Azarbal F, Singh M, Finocchiaro G, et al. Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart. 2014;100(8):624-30. doi:10.1136/heartjnl-2013-304908.
367. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-100. doi:10.1378/chest.10-0134.
368. Lee HJ, Kim HK, Jung JH, et al. Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation. Stroke. 2019;50(9):2582-6. doi:10.1161/STROKEAHA.119.026048.
369. Dominguez F, Climent V, Zorio E, et al. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. Int J Cardiol. 2017;248:232-8. doi:10.1016/j.ijcard.2017.08.010.
370. Li B, Sun C, Qin F, et al. Could direct oral anticoagulants be an alternative to vitamin K antagonists in patients with hypertrophic cardiomyopathy and atrial fibrillation? Int J Cardiol. 2018;256:39. doi:10.1016/j.ijcard.2017.10.113.
371. Lozier MR, Sanchez AM, Lee JJ, et al. Thromboembolic Outcomes of Different Anticoagulation Strategies for Patients with Atrial Fibrillation in the Setting of Hypertrophic Cardiomyopathy: A Systematic Review. J Atr Fibrillation. 2019;12(4):2207. doi:10.4022/jafib.2207.
372. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. doi:10.1016/S0140-6736(13)62343-0.
373. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi:10.1056/NEJMoa0905561. Erratum in: N Engl J Med. 2010;363(19):1877.
374. Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, et al. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis. 2013;2013:640723. doi:10.1155/2013/640723.
375. Клинические рекомендации. Фибрилляция предсердий. Москва, 2017. 65 с. https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf.
376. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066-78. doi:10.1056/NEJMoa0901301.
377. Бокерия Л. А., Бокерия О.Л., Меликулов А. Х. и др. Хирургическое лечение фибрилляции предсердий: современное состояние проблемы. Анналы аритмологии. 2009;6(2):5-11.
378. Nishimura RA, Schaff HV. Septal myectomy for patients with hypertrophic cardiomyopathy: A new paradigm. J Thorac Cardiovasc Surg. 2016;151(2):303-4. doi:10.1016/j.jtcvs.2015.09.068.
379. Swistel DG, Balaram SK. Surgical myectomy for hypertrophic cardiomyopathy in the 21st century, the evolution of the "RPR" repair: resection, plication, and release. Prog Cardiovasc Dis. 2012;54(6):498-502. doi:10.1016/j.pcad.2012.03.001.
380. Swistel DG, Sherrid MV. The surgical management of obstructive hypertrophic cardiomyopathy: the RPR procedure-resection, plication, release. Ann Cardiothorac Surg. 2017;6(4):423-5. doi:10.21037/acs.2017.06.03.
381. Veselka J, Jensen MK, Liebregts M, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37(19):1517-23. doi:10.1093/eurheartj/ehv693.
382. Afanasyev AV, Bogachev-Prokophiev AV, Kashtanov MG, et al. Myectomy versus alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Interact Cardiovasc Thorac Surg. 2020;31(2):158-65. doi:10.1093/icvts/ivaa075.
383. Bogachev-Prokophiev A, Afanasyev A, Zheleznev S, et al. Mitral valve repair or replacement in hypertrophic obstructive cardiomyopathy: a prospective randomized study. Interact Cardiovasc Thorac Surg. 2017;25(3):356-62. doi:10.1093/icvts/ivx152.
384. Bogachev-Prokophiev A, Afanasyev AV, Zheleznev S, et al. Septal Myectomy With Vs Without Subvalvular Apparatus Intervention in Patients With Hypertrophic Obstructive Cardiomyopathy: A Prospective Randomized Study. Semin Thorac Cardiovasc Surg. 2019;31(3):424-31. doi:10.1053/j.semtcvs.2019.01.011.
385. Afanasyev A, Bogachev-Prokophiev A, Lenko E, et al. Myectomy with mitral valve repair versus replacement in adult patients with hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2019;28(3):465-72. doi:10.1093/icvts/ivy269.
386. Гурщенков А. В., Сухова И. В., Зайцев В. В. и др. Пятилетний опыт использования мобилизации сердца при септальной миоэктомии. Кардиология и сердечно-сосудистая хирургия. 2018;11(4):54-8. doi:10.17116/kardio201811454.
387. Agarwal S, Tuzcu EM, Desai MY, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55(8):823-34. doi:10.1016/j.jacc.2009.09.047.
388. Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. Eur Heart J. 2009;30(9):1080-7. doi:10.1093/eurheartj/ehp016.
389. Swistel DG, Balaram SK. Resection, Plication, Release – the RPR procedure for obstructive hypertrophic cardiomyopathy. Anadolu Kardiyol Derg. 2006;6 Suppl 2:31-6.
390. Каштанов М. Г., Чернышев С. Д., Кардапольцев Л. В. и др. Этаноловая септальная аблация в лечении обструктивной гипертрофической кардиомиопатии: отбор пациентов и рациональность ее применения. Патология кровообращения и кардиохирургия. 2017;21(1):104-16.
391. Batzner A, Schäfers HJ, Borisov KV, Seggewiß H. Hypertrophic obstructive cardiomyopathy – the role of myectomy and percutaneous septal ablation in drug-refractory disease. Dtsch Arztebl Int. 2019;116:47-53. doi:10.3238/arztebl.2019.0047.
392. Сухов В. К., Шлойдо Е. А., Шубенок Д. А. и др. Спиртовая септальная абляция при обструктивной гипертрофической кардиомиопатии. Международный журнал интервенционной кардиоангиологии. 2013;(35):75.
393. Schaff HV, Dearani JA, Ommen SR, et al. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: results of operation in patients with latent obstruction. J Thorac Cardiovasc Surg. 2012;143(2):303-9. doi:10.1016/j.jtcvs.2011.10.059.
394. McCully RB, Nishimura RA, Tajik AJ, et al. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation. 1996;94(3):467-71. doi:10.1161/01.cir.94.3.467.
395. Orme NM, Sorajja P, Dearani JA, et al. Comparison of surgical septal myectomy to medical therapy alone in patients with hypertrophic cardiomyopathy and syncope. Am J Cardiol. 2013;111(3):388-92. doi:10.1016/j.amjcard.2012.10.014.
396. Halpern DG, Swistel DG, Po JR, et al. Echocardiography before and after resect-plicate-release surgical myectomy for obstructive hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2015;28(11):1318-28. doi:10.1016/j.echo.2015.07.002.
397. Kaple RK, Murphy RT, DiPaola LM, et al. Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes. Ann Thorac Surg. 2008;85(5):1527-35, 1535.e1-2. doi:10.1016/j.athoracsur.2008.01.061.
398. Kofflard MJ, van Herwerden LA, Waldstein DJ, et al. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1996;28(1):197-202. doi:10.1016/0735-1097(96)00103-9.
399. Schoendube FA, Klues HG, Reith S, et al. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation. 1995;92(9 Suppl):II122-7. doi:10.1161/01.cir.92.9.122.
400. Steggerda RC, Damman K, Balt JC, et al. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. JACC Cardiovasc Interv. 2014;7(11):1227-34. doi:10.1016/j.jcin.2014.05.023.
401. Богачев-Прокофьев А. В., Железнев С. И., Фоменко М. С. и др. Эффективность расширенной миоэктомии у пациентов с желудочковой обструкцией при гипертрофической кардиомиопатии. Кардиология. 2017;57(5):38-43. doi:10.18565/cardio.2017.5.38-43.
402. Borisov KV. Right ventricle myectomy. Ann Cardiothorac Surg. 2017;6(4):402-9. doi:10.21037/acs.2017.07.10.
403. Wehman B, Ghoreishi M, Foster N, et al. Transmitral Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy. Ann Thorac Surg. 2018;105(4):1102-8. doi:10.1016/j.athoracsur.2017.10.045.
404. Бокерия Л. А. Гипертрофическая обструктивная кардиомиопатия. Анналы хирургии. 2013;(5):5-14.
405. Takahashi J, Wakamatsu Y, Okude J, et al. Septal myectomy, papillary muscle resection, and mitral valve replacement for hypertrophic obstructive cardiomyopathy: a case report. Ann Thorac Cardiovasc Surg. 2008;14(4):258-62.
406. Cooley DA, Wukasch DC, Leachman RD. Mitral valve replacement for idiopathic hypertrophic subaortic stenosis. Results in 27 patients. J Cardiovasc Surg (Torino). 1976t;17(5):380-7.
407. Stassano P, Di Tommaso L, Triggiani D, et al. Mitral valve replacement and limited myectomy for hypertrophic obstructive cardiomyopathy: a 25-year follow-up. Tex Heart Inst J. 2004;31(2):137-42.
408. Reis RL, Bolton MR, King JF, et al. Anterion-superior displacement of papillary muscles producing obstruction and mitral regurgitation in idiopathic hypertrophic subaortic stenosis. Operative relief by posterior-superior realignment of papillary muscles following ventricular septal myectomy. Circulation. 1974;50(2 Suppl):II181-8.
409. Shimahara Y, Fujita T, Kobayashi J, et al. Combined mechanical mitral valve replacement and transmitral myectomy for hypertrophic obstructive cardiomyopathy treatment: An experience of over 20 years. J Cardiol. 2019;73(4):318-25. doi:10.1016/j.jjcc.2018.12.012.
410. Topilski I, Sherez J, Keren G, Copperman I. Long-term effects of dual-chamber pacing with periodic echocardiographic evaluation of optimal atrioventricular delay in patients with hypertrophic cardiomyopathy >50 years of age. Am J Cardiol. 2006;97(12):1769-75. doi:10.1016/j.amjcard.2006.01.040.
411. Хирманов В. Н., Юзвинкевич С. А., Домашенко А. А. и др. Отдаленные результаты лечения гипертрофической кардиомиопатии с помощью постоянной двукамерной электрокардиостимуляции. Кардиология. 2002;(8):46-7.
412. Трешкур Т. В., Крутиков А. Н., Хирманов В. Н. и др. Внутрисердечная гемодинамика у больных с гипертрофической кардиомиопатией при лечении постоянной двухкамерной электрокардиостимуляцией. Вестник аритмологии. 1995;(4):248-9.
413. Daubert C, Gadler F, Mabo P, Linde C. Pacing for hypertrophic obstructive cardiomyopathy: an update and future directions. Europace. 2018;20(6):908-20. doi:10.1093/europace/eux131.
414. Quintana E, Cox JL. Surgical management of atrial fibrillation at the time of septal myectomy. Ann Cardiothorac Surg. 2017;6(4):386-93. doi:10.21037/acs.2017.05.08.
415. Бокерия Л. А., Бокерия О. Л., Климчук И. Я., Санакоев М. К. Хирургическая коррекция обструктивной гипертрофической кардиомиопатии с SAM-синдромом и фибрилляцией предсердий. Анналы аритмологии. 2016;13(4):216-21. doi:10.15275/annaritmol.2016.4.4.
416. Бокерия Л. А., Тетвадзе И. В., Маленков Д. А., Санакоев М. К. Сочетанная операция миоэктомии межжелудочковой перегородки из правого желудочка и эпикардиальная криомодификация операции «лабиринт». Анналы аритмологии. 2013;10(2):64-8. doi:10.15275/annaritmol.2013.2.1.
417. Bogachev-Prokophiev AV, Afanasyev AV, Zheleznev SI, et al. Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg. 2018;155(4):1536-42.e2. doi:10.1016/j.jtcvs.2017.08.063.
418. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003;42(5):873-9. doi:10.1016/s0735-1097(03)00827-1.
419. Task Force for the Diagnosis and Management of Syncope; European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS), Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J. 2009;30(21):2631-71. doi:10.1093/eurheartj/ehp298.
420. Sherrid MV, Massera D. Risk Stratification and Hypertrophic Cardiomyopathy Subtypes. J Am Coll Cardiol. 2019;74(19):2346-9. doi:10.1016/j.jacc.2019.09.020.
421. Mentias A, Raeisi-Giglou P, Smedira NG, et al. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function. J Am Coll Cardiol. 2018;72(8):857-70. doi:10.1016/j.jacc.2018.05.060. Erratum in: J Am Coll Cardiol. 2018;72(14):1761.
422. Трансплантация сердца и механическая поддержка кровообращения. Национальные клинические рекомендации. 2016. 115 с. https://sudact.ru/law/natsionalnye-klinicheskie-rekomendatsii-transplantatsiia-serdtsa-i-mekhanicheskaia/natsionalnye-klinicheskie-rekomendatsii/.
423. Topilsky Y, Pereira NL, Shah DK, et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail. 2011;4(3):266-75. doi:10.1161/CIRCHEARTFAILURE.110.959288.
424. Biagini E, Spirito P, Leone O, et al. Heart transplantation in hypertrophic cardiomyopathy. Am J Cardiol. 2008;101(3):387-92. doi:10.1016/j.amjcard.2007.09.085.
425. Диагностика и лечение сердечно-сосудистых заболеваний при беременности 2018. Национальные рекомендации. Российский кардиологический журнал. 2018;(3):91-134. doi:10.15829/1560-4071-2018-3-91-134.
426. Goland S, van Hagen IM, Elbaz-Greener G, et al. Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). Eur Heart J. 2017;38(35):2683-90. doi:10.1093/eurheartj/ehx189.
427. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al.; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-241. doi:10.1093/eurheartj/ehy340.
428. Bowyer L. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer 2003-2005. The Seventh Report of the Confidential Enquiries into Maternal Deaths in the UK. Obstet. Med. 2008;1(1):54-54. doi:10.1258/om.2008.080017.
429. Billebeau G, Etienne M, Cheikh-Khelifa R, et al. Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort. Arch Cardiovasc Dis. 2018;111(3):199-209. doi:10.1016/j.acvd.2017.05.010.
430. Krul SP, van der Smagt JJ, van den Berg MP, et al. Systematic review of pregnancy in women with inherited cardiomyopathies. Eur J Heart Fail. 2011;13(6):584-94. doi:10.1093/eurjhf/hfr040.
431. Tromp CH, Nanne AC, Pernet PJ, et al. Electrical cardioversion during pregnancy: safe or not? Neth Heart J. 2011;19(3):134-6. doi:10.1007/s12471-011-0077-5.
432. Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118(15):1541-9. doi:10.1161/CIRCULATIONAHA.108.781401.
433. Burton H, Alberg C, Stewart A. Heart to Heart: Inherited Cardiovascular Conditions Services – A Needs Assessment and Service Review. 2009. 163 p. ISBN: 978-1-907198-01-4.
434. Canepa M, Pozios I, Vianello PF, et al. Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly. Heart. 2016;102(14):1087-94. doi:10.1136/heartjnl-2015-308764.
435. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. doi:10.1136/bmj.d124.
436. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173-80. doi:10.1016/j.jacc.2010.09.024.